Imaging tech measures tissue oxygenation for better healing

Kent Imaging and SerenaGroup announce strategic partnership in wound care

Register for free to listen to this article
Listen with Speechify
CALGARY—Kent Imaging Inc. and SerenaGroup have announced a Strategic Partnership to jointly improve tissue assessment in wounds with the use of Near Infrared Imaging technology using Kent’s KD203 device. According to Kent’s website, the KD203 device is “the newest advancement in tissue oxygenation and perfusion imaging. Providing improved decision making throughout the dynamic treatment pathway – before, during and after wound or surgical care.”
Oxygenation is widely accepted as the best biomarker of tissue health and healing. Kent's device is intended for use by healthcare professionals as a non-invasive tissue oxygenation measurement system that reports oxygen saturation (StO2), relative oxyhemoglobin level (HbO2), and relative deoxyhemoglobin (Hb) level in superficial tissue. Kent’s multispectral imaging technology displays two-dimensional color-coded images providing critical information to help clinicians determine at risk tissue and guide treatments to optimize patient outcomes in wound care, plastic surgery, and various other reconstructive applications.
“We are pleased to introduce Kent’s imaging system into the wound care protocol at our clinics. One of the most troublesome and elusive criteria in treating wounds is the timely and accurate assessment of viable tissue,” said Thomas E. Serena, MD FACS FACHM MAPWCA, Founder and Medical Director of SerenaGroup. “Kent’s device will propel us a long way down the healing path with a technology that has been lacking across the board in the Wound Care space.”

This is a great partnership between one of the leaders in building wound care teams and an innovative tissue assessment technology that is easy to use, convenient, and cost effective. SerenaGroup will adopt Kent Imaging’s technology as the standard of care for assessing wound oxygenation and thus wound health. Kent will be integrated into each of the SerenaGroup-managed facilities, included in Hyperbaric training courses curriculum, as well as included in future clinical and preclinical research.
“Our joint belief is that we can improve patient care and outcomes by significantly improving clinically relevant data that is required to assess and manage wounds,” added Pierre Lemire, CEO of Kent Imaging. “We are excited to be partnering with SerenaGroup and with Dr. Serena, who has dedicated his career to improving patient outcomes in wound care.”
Kent’s Tissue Oxygenation Assessment device is a cordless handheld portable which can instantly assess tissue, suitable for use in all care settings. The device is non-invasive, with no injectables or dyes. The oxygenation assessment device is an accurate means to track patient progress and treatment effectiveness. It provides quantified tissue oxygenation levels without disruption to existing workflow, it has unlimited imaging and storage, and is reportedly easy to use with minimal training required. It is also a low cost device without disposables or pay per click fees. Kent is available for sale in the United States, Canada, and Europe with FDA Class II clearance, Health Canada clearance, and CE Mark.

Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

DDN Magazine May 2024

Latest Issue  

• Volume 20 • Issue 3 • May 2024

May 2024

May 2024 Issue